ANCA-associated Vasculitis — Research Summary
Printed from RareWays (rareways.com.au) on 25 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Urinary NGAL and trehalase predict end-stage kidney disease in ANCA-associated vasculitis: a prospective cohort study.
Qiu Miaohua et al. — Renal failure (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42021629/
- 2.
Integrative transcriptomic and machine learning analysis identifies PYCARD and IFI30 as immune-lysosomal biomarkers of ANCA-associated glomerulonephritis.
Bei Liyuan et al. — Renal failure (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41668326/
- 3.
Imaging of Extra-nodal Head and Neck Lymphoma and its Mimics.
Gad Mona et al. — European journal of radiology (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42235460/
- 4.
Isolated nasal septal involvement in granulomatosis with polyangiitis: Radiologic features and literature review.
Bouallou Mohamed et al. — Radiology case reports (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42232148/
- 5.
[Diffuse bilateral pulmonary infiltrates with multiorgan involvement].
Jiao Y et al. — Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (12 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42373452/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Recruiting — Phase 1 — Nkarta, Inc.
https://clinicaltrials.gov/study/NCT06733935
- 2.
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Recruiting — Phase 2 — Alexion Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT07160608
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
ANCA-associated Vasculitis
ANCA-associated Vasculitis is a group of rare autoimmune diseases characterised by inflammation of small blood vessels, associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys and lungs and can be rapidly progressive. Without treatment it carries high mortality, but outcomes have improved substantially with immunosuppressive therapy and rituximab.
Most Recent Research
BACKGROUND: Accurate prediction of renal outcomes in ANCA-associated vasculitis (AAV) is critical. This study evaluated the predictive value of urinary biomarkers for end-stage kidney disease (ESKD) progression. METHODS: A prospective cohort of 88 AAV patients with renal involvement was followed for a median of 27 months. Urinary β-catenin, IL-18, trehalase, and NGAL were measured. Cox regression and ROC analyses assessed associations and predictive performance. RESULTS: 65 patients (73.9%) progressed to ESKD. Urinary trehalase and NGAL were significantly elevated in the ESKD group and were independent predictors of ESKD in multivariable analysis (both p < 0.05), with AUCs of 0.857 and 0.852, respectively. Their combination improved predictive accuracy (AUC = 0.869). β-catenin showed moderate predictive value (AUC = 0.705). Although urinary IL-18 showed statistical significance when analyzed as a continuous variable in an initial model, this association was not consistent across alternative modeling strategies and therefore was not considered a stable independent predictor. Stratified and landmark analyses confirmed the robustness of trehalase and NGAL's prognostic value. CONCLUSION: Urinary trehalase and NGAL are strong, noninvasive predictors of ESKD in AAV, and their combination enhances risk stratification, supporting potential clinical utility for personalized treatment decisions.
Common Questions
What is ANCA-associated Vasculitis?
ANCA-associated Vasculitis is a group of rare autoimmune diseases characterised by inflammation of small blood vessels, associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys and lungs and can be rapidly progressive. Without treatment it carries high mortality, but outcomes have improved substantially with immunosuppressive therapy and rituximab.
How many clinical trials are available for ANCA-associated Vasculitis?
RareWays currently indexes 173 clinical trials for ANCA-associated Vasculitis, of which 67 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for ANCA-associated Vasculitis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for ANCA-associated Vasculitis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.